Docking‐based approach for identification of mutations that disrupt binding between Bcl‐2 and Bax proteins: Inducing apoptosis in cancer cells

Abstract Background Inducing apoptosis in cancer cells is an important step for the successful treatment of cancer patients. Bcl‐2 is an antiapoptotic protein which determines apoptosis by interacting with proapoptotic members of the Bcl‐2 family. Exome sequencing has identified Bcl‐2 and Bax missen...

Full description

Bibliographic Details
Main Authors: Pawan Kumar Raghav, Rajesh Kumar, Vinod Kumar, Gajendra P. S. Raghava
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Molecular Genetics & Genomic Medicine
Subjects:
Online Access:https://doi.org/10.1002/mgg3.910
_version_ 1797296142672723968
author Pawan Kumar Raghav
Rajesh Kumar
Vinod Kumar
Gajendra P. S. Raghava
author_facet Pawan Kumar Raghav
Rajesh Kumar
Vinod Kumar
Gajendra P. S. Raghava
author_sort Pawan Kumar Raghav
collection DOAJ
description Abstract Background Inducing apoptosis in cancer cells is an important step for the successful treatment of cancer patients. Bcl‐2 is an antiapoptotic protein which determines apoptosis by interacting with proapoptotic members of the Bcl‐2 family. Exome sequencing has identified Bcl‐2 and Bax missense mutations in more than 40 cancer types. However, a little information is available about the functional impact of each Bcl‐2 and Bax mutation on the pathogenesis of cancer. Methods The mutational data from cancer tissues and cell lines were retrieved from the cBioPortal web resource. The 13 mutated Bcl‐2 and wild‐type Bax complexes with experimentally verified binding were identified from previous studies wherein, binding for all complexes was reportedly disrupted except one. Several protein–protein docking methods such as ClusPro, HDOCK, PatchDock, FireDock, InterEVDock2 and several mutation prediction methods such as PolyPhen‐2, SIFT, and OncoKB have been used to predict the effect of mutation to disrupt the binding between Bcl‐2 and Bax. The result obtained was compared with the known experimental data. Results The protein–protein docking method, ClusPro, employed in the present study confirmed that the binding affinity of 11 out of 13 complexes decreases. Similarly, binding affinity computed for all the 10 wild‐type Bcl‐2 and mutated Bax complexes agreed with experimentally verified results. Conclusion Several methods like PolyPhen‐2, SIFT, and OncoKB have been developed to predict cancer‐associated or deleterious mutations, but no method is available to predict apoptosis‐inducing mutations. Thus, in this study, we have examined the mutations in Bcl‐2 and Bax proteins that disrupt their binding, which is crucial for inducing apoptosis to eradicate cancer. This study suggests that protein–protein docking methods can play a significant role in the identification of hotspot mutations in Bcl‐2 or Bax that can disrupt their binding with wild‐type partner to induce apoptosis in cancer cells.
first_indexed 2024-03-07T21:59:06Z
format Article
id doaj.art-6e9ce13d5938437bbf8cc675fe426425
institution Directory Open Access Journal
issn 2324-9269
language English
last_indexed 2024-03-07T21:59:06Z
publishDate 2019-11-01
publisher Wiley
record_format Article
series Molecular Genetics & Genomic Medicine
spelling doaj.art-6e9ce13d5938437bbf8cc675fe4264252024-02-24T07:01:11ZengWileyMolecular Genetics & Genomic Medicine2324-92692019-11-01711n/an/a10.1002/mgg3.910Docking‐based approach for identification of mutations that disrupt binding between Bcl‐2 and Bax proteins: Inducing apoptosis in cancer cellsPawan Kumar Raghav0Rajesh Kumar1Vinod Kumar2Gajendra P. S. Raghava3Center for Computational Biology Indraprastha Institute of Information Technology New Delhi IndiaCenter for Computational Biology Indraprastha Institute of Information Technology New Delhi IndiaCenter for Computational Biology Indraprastha Institute of Information Technology New Delhi IndiaCenter for Computational Biology Indraprastha Institute of Information Technology New Delhi IndiaAbstract Background Inducing apoptosis in cancer cells is an important step for the successful treatment of cancer patients. Bcl‐2 is an antiapoptotic protein which determines apoptosis by interacting with proapoptotic members of the Bcl‐2 family. Exome sequencing has identified Bcl‐2 and Bax missense mutations in more than 40 cancer types. However, a little information is available about the functional impact of each Bcl‐2 and Bax mutation on the pathogenesis of cancer. Methods The mutational data from cancer tissues and cell lines were retrieved from the cBioPortal web resource. The 13 mutated Bcl‐2 and wild‐type Bax complexes with experimentally verified binding were identified from previous studies wherein, binding for all complexes was reportedly disrupted except one. Several protein–protein docking methods such as ClusPro, HDOCK, PatchDock, FireDock, InterEVDock2 and several mutation prediction methods such as PolyPhen‐2, SIFT, and OncoKB have been used to predict the effect of mutation to disrupt the binding between Bcl‐2 and Bax. The result obtained was compared with the known experimental data. Results The protein–protein docking method, ClusPro, employed in the present study confirmed that the binding affinity of 11 out of 13 complexes decreases. Similarly, binding affinity computed for all the 10 wild‐type Bcl‐2 and mutated Bax complexes agreed with experimentally verified results. Conclusion Several methods like PolyPhen‐2, SIFT, and OncoKB have been developed to predict cancer‐associated or deleterious mutations, but no method is available to predict apoptosis‐inducing mutations. Thus, in this study, we have examined the mutations in Bcl‐2 and Bax proteins that disrupt their binding, which is crucial for inducing apoptosis to eradicate cancer. This study suggests that protein–protein docking methods can play a significant role in the identification of hotspot mutations in Bcl‐2 or Bax that can disrupt their binding with wild‐type partner to induce apoptosis in cancer cells.https://doi.org/10.1002/mgg3.910apoptosisBaxBcl‐2cancerdockingmutation
spellingShingle Pawan Kumar Raghav
Rajesh Kumar
Vinod Kumar
Gajendra P. S. Raghava
Docking‐based approach for identification of mutations that disrupt binding between Bcl‐2 and Bax proteins: Inducing apoptosis in cancer cells
Molecular Genetics & Genomic Medicine
apoptosis
Bax
Bcl‐2
cancer
docking
mutation
title Docking‐based approach for identification of mutations that disrupt binding between Bcl‐2 and Bax proteins: Inducing apoptosis in cancer cells
title_full Docking‐based approach for identification of mutations that disrupt binding between Bcl‐2 and Bax proteins: Inducing apoptosis in cancer cells
title_fullStr Docking‐based approach for identification of mutations that disrupt binding between Bcl‐2 and Bax proteins: Inducing apoptosis in cancer cells
title_full_unstemmed Docking‐based approach for identification of mutations that disrupt binding between Bcl‐2 and Bax proteins: Inducing apoptosis in cancer cells
title_short Docking‐based approach for identification of mutations that disrupt binding between Bcl‐2 and Bax proteins: Inducing apoptosis in cancer cells
title_sort docking based approach for identification of mutations that disrupt binding between bcl 2 and bax proteins inducing apoptosis in cancer cells
topic apoptosis
Bax
Bcl‐2
cancer
docking
mutation
url https://doi.org/10.1002/mgg3.910
work_keys_str_mv AT pawankumarraghav dockingbasedapproachforidentificationofmutationsthatdisruptbindingbetweenbcl2andbaxproteinsinducingapoptosisincancercells
AT rajeshkumar dockingbasedapproachforidentificationofmutationsthatdisruptbindingbetweenbcl2andbaxproteinsinducingapoptosisincancercells
AT vinodkumar dockingbasedapproachforidentificationofmutationsthatdisruptbindingbetweenbcl2andbaxproteinsinducingapoptosisincancercells
AT gajendrapsraghava dockingbasedapproachforidentificationofmutationsthatdisruptbindingbetweenbcl2andbaxproteinsinducingapoptosisincancercells